XOMA Corporation (XOMA)

NASDAQ: XOMA · IEX Real-Time Price · USD
21.34 0.45 (2.15%)
Jan 21, 2022 4:00 PM EST - Market closed
Market Cap241.38M
Revenue (ttm)29.80M
Net Income (ttm)5.43M
Shares Out11.31M
EPS (ttm)0.08
PE Ratio260.24
Forward PE31.06
Dividendn/a
Ex-Dividend Daten/a
Volume44,359
Open20.66
Previous Close20.89
Day's Range20.66 - 21.63
52-Week Range19.40 - 44.50
Beta0.81
AnalystsBuy
Price Target62.50 (+192.9%)
Earnings Daten/a

About XOMA

XOMA Corporation, a biotechnology royalty aggregator, engages in helping biotech companies for improving human health. The company acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. It acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance internal drug candidate or for general corporate purposes. The company has a portfolio with approximately 70 assets. XOMA Corporation was inco...

IndustryBiotechnology
CEOJames Neal
Employees12
Stock ExchangeNASDAQ
Ticker SymbolXOMA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for XOMA stock is "Buy." The 12-month stock price forecast is 62.50, which is an increase of 192.88% from the latest price.

Price Target
$62.50
(192.88% upside)
Analyst Consensus: Buy

News

XOMA Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., Dec. 23, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to hold...

1 month ago - GlobeNewsWire

XOMA to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving ...

1 month ago - GlobeNewsWire

XOMA Announces Evolution of Company Leadership and Succession Planning

Chief Executive Officer Jim Neal appointed as Chairman; Former Chairman W. Denman Van Ness to remain Lead Independent Director

1 month ago - GlobeNewsWire

Xoma (XOMA) Reports Q3 Loss, Misses Revenue Estimates

Xoma (XOMA) delivered earnings and revenue surprises of -466.67% and -85.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

XOMA Earns $35 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic...

EMERYVILLE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) announced today NIS793, an anti-TGFβ monoclonal antibody licensed from the Company, has advanced to the Phase 3 deve...

2 months ago - GlobeNewsWire

XOMA Reports Third Quarter 2021 Financial Results and Highlights Recent Operational Events

Added eight assets to its portfolio of potential milestone and royalty assets in 2021

2 months ago - GlobeNewsWire

Will Xoma (XOMA) Report Negative Q3 Earnings? What You Should Know

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Strength Seen in Xoma (XOMA): Can Its 11.2% Jump Turn into More Strength?

Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

3 months ago - Zacks Investment Research

XOMA to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

EMERYVILLE, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA)'s Chief Executive Officer, Jim Neal, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conferenc...

4 months ago - GlobeNewsWire

XOMA to Present at H.C. Wainwright 23rd Annual Global Investment Conference

EMERYVILLE, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright 23rd Annual Global Inves...

4 months ago - GlobeNewsWire

XOMA Announces Heather L. Franklin Joins its Board of Directors

EMERYVILLE, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today Heather L. Franklin, President and Chief Executive Officer of Blaze Bioscience, Inc., has joined the...

5 months ago - GlobeNewsWire

Recap: XOMA Q2 Earnings

Shares of XOMA (NASDAQ:XOMA) were flat after the company reported Q2 results. Quarterly Results Earnings per share increased 12.12% over the past year to ($0.29), which beat the estimate of ($0.35).

5 months ago - Benzinga

Xoma (XOMA) Reports Q2 Loss, Misses Revenue Estimates

Xoma (XOMA) delivered earnings and revenue surprises of 24.39% and -56.89%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

XOMA Reports Second Quarter 2021 Financial Results and Highlights Recent Operational Events

Added six assets to its portfolio of potential milestone and royalty assets in 2021

5 months ago - GlobeNewsWire

Earnings Preview: Xoma (XOMA) Q2 Earnings Expected to Decline

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

U.S. Food and Drug Administration has Granted Orphan Drug Designation to XOMA's Licensed anti-TGFβ Asset NIS793

EMERYVILLE, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today NIS793 in combination with standard of care chemotherapy has been granted Orphan Drug Designation i...

5 months ago - GlobeNewsWire

XOMA Buys Royalty, Milestone Interest In Checkmate's Vidutolimod From Kuros Biosciences

XOMA Corporation (NASDAQ: XOMA) has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals Inc's (NASDAQ: CMPI) vidutolimod (CMP-001), for $7.0 million upfront plus ...

6 months ago - Benzinga

Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agree...

Ad hoc announcement pursuant to Article 53 of the SIX listing rules Ad hoc announcement pursuant to Article 53 of the SIX listing rules

6 months ago - GlobeNewsWire

XOMA Acquires Royalty and Milestone Interest in Checkmate's Vidutolimod (CMP-001) from Kuros Biosciences

EMERYVILLE, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals'...

6 months ago - GlobeNewsWire

XOMA Licensees to Present Significant Clinical Data at 2021 ASCO Annual Meeting

EMERYVILLE, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) recently learned its licensees are presenting at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annua...

8 months ago - GlobeNewsWire

Xoma (XOMA) Reports Q1 Loss, Misses Revenue Estimates

Xoma (XOMA) delivered earnings and revenue surprises of -366.67% and -69.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

XOMA Reports First Quarter 2021 Financial Results and Highlights Recent Operational Events

XOMA's portfolio of potential milestone and royalty assets now has greater than 70 drug candidates. Company ended the first quarter of 2021 with $67.8 million in cash.  The April 2021 $40 million Series...

8 months ago - GlobeNewsWire

XOMA Earns Milestone for First Patient Dosed in Phase 3 Development Program

EMERYVILLE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $0.5 million milestone from Janssen Biotech, Inc. (Janssen)...

8 months ago - GlobeNewsWire

XOMA's Royalty Portfolio Grows with Addition of Three Royalty Assets

EMERYVILLE, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) today announced its portfolio of potential future milestone and royalty assets has increased with the addition of t...

9 months ago - GlobeNewsWire

XOMA Announces Closing of Depositary Shares Offering and Exercise of Underwriters' Option

Raised aggregate gross proceeds of $40 million

9 months ago - GlobeNewsWire